SynthesisFrontiers in oncology2020
Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis.
Synthesis in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- JS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study.Precision clinical medicine · 2026Article
- Dietary patterns and knowledge-attitude-practice factors are associated with late recurrence of non-muscle-invasive bladder cancer: a case-control study.Frontiers in nutrition · 2026Article
- Recurrence and prevention strategies for non-muscle-invasive bladder cancer: A comprehensive review.Asian journal of urology · 2026Review
- Article
- Hyperthermic intravesical chemotherapy with gemcitabine versus Bacillus Calmette-Guerin in intermediate- and high-risk non-muscle-invasive bladder cancer.Frontiers in oncology · 2025Article
- Development of Novel Intravesical Formulation for Bladder Retention Targeting Bladder Disorders.Current drug targets · 2025Review
- Perfusion drugs for non‑muscle invasive bladder cancer (Review).Oncology letters · 2024Review
- Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.International urology and nephrology · 2024Article
- Perturbation of Copper Homeostasis Sensitizes Cancer Cells to Elevated Temperature.International journal of molecular sciences · 2023Article
- A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer.Scientific reports · 2022Article
- Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments.Archives of pharmacology and therapeutics · 2022Article
- Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma.Frontiers in oncology · 2022Article
- 5-Methylcytosine-Related Long Noncoding RNAs Are Potential Biomarkers to Predict Overall Survival and Regulate Tumor-Immune Environment in Patients with Bladder Cancer.Disease markers · 2022Article
- Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence.Journal of healthcare engineering · 2021Article
- Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews.ClinicoEconomics and outcomes research : CEOR · 2020Review
- Evaluating repeat transurethral resection after en bloc resection for non-muscle invasive bladder cancer.Therapeutic advances in urologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.